It looks like you're using an Ad Blocker.

Please white-list or disable in your ad-blocking tool.

Thank you.


Some features of ATS will be disabled while you continue to use an ad-blocker.


Jennifer Haller and the other Vaccine human test subjects.

page: 1

log in


posted on Mar, 19 2020 @ 01:23 AM

Jennifer Haller is the Seattle woman who volunteered to be the first person to test an experimental vaccine that was developed to potentially help guard against the coronavirus. Haller received the first of two injections on March 16. The medical trial is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle.

infoCNN chat

Wonder if there will be open and free information on her and all other test subjects? Say like the daily vblogs of David Abel.

Does any one know if they are planning on the keeping a public interest or is there took much interest in Big Brother season 51 too many?

posted on Mar, 19 2020 @ 01:26 AM
a reply to: puzzled2

Clinic trials are an involved process. They involve statistical analysis of groups of test subjects.

There will not be ongoing updates because there will be no results until the trials are completed.

The first phase of testing is for safety, not efficacy.

edit on 3/19/2020 by Phage because: (no reason given)

posted on Mar, 19 2020 @ 02:39 AM
a reply to: Phage

So will there will be open and free information on her and all other test subjects?

Would not there be 'results' prior to the 'trials' being 'completed' that would be available for public analysis?

I guess everyone is just supposed to sit around and wait for all of the results from the trials to be completed by a single entity controlling the testing and reporting.

posted on Mar, 19 2020 @ 03:29 AM
a reply to: puzzled2

There's a little more information here from the NIH:

NIH clinical trial of investigational vaccine for COVID-19 begins

The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine.

The Phase 1 trial is led by Lisa A. Jackson, M.D., senior investigator at KPWHRI. Study participants will receive two doses of the vaccine via intramuscular injection in the upper arm approximately 28 days apart. Each participant will be assigned to receive a 25 microgram (mcg), 100 mcg or 250 mcg dose at both vaccinations, with 15 people in each dose cohort. The first four participants will receive one injection with the low dose, and the next four participants will receive the 100 mcg dose. Investigators will review safety data before vaccinating the remaining participants in the 25 and 100 mcg dose groups and before participants receive their second vaccinations. Another safety review will be done before participants are enrolled in the 250 mcg cohort.

Participants will be asked to return to the clinic for follow-up visits between vaccinations and for additional visits across the span of a year after the second shot. Clinicians will monitor participants for common vaccination symptoms, such as soreness at the injection site or fever as well as any other medical issues. A protocol team will meet regularly to review safety data, and a safety monitoring committee will also periodically review trial data and advise NIAID. Participants also will be asked to provide blood samples at specified time points, which investigators will test in the laboratory to detect and measure the immune response to the experimental vaccine.

Unless serious safety concerns come up, I doubt we will hear anything until the course is completed and they can analyze the results.

posted on Mar, 19 2020 @ 04:28 AM
a reply to: puzzled2

When does she turn into a zombie?

T virus and counting...

posted on Mar, 19 2020 @ 11:14 AM
Husband says the way they would do this with the waiving of the regs like they have is to go with the lowest possible dose they consider might provoke a response and then start working their way up to larger doses until the subjects complain of some sort of side effect in order to determine a safe dosage level of antigen.

Once they that, they'll look at formation of immunity and duration, but they aren't going to outright sacrifice people.

They're just going to cut corners where they can, and with the current reg regime there are plenty of places this can be done. The actual procedures for making a vaccine are well-understood; it's establishing dosage that takes the fine-tuning. Most of the regs in place are for getting the minimal effective dose in order to reduce chances of adverse reactions, but understand in this case that adverse reaction could be getting a rash or hives as much as the severe reactions we're all thinking of.

new topics

top topics

log in